Self-microemulsion preparation of axitinib
Patent Information
- Authority / Receiving Office
- CN · China
- Current Assignee / Owner
- HUNAN HUIZE BIO PHARMA CO LTD
- Publication Date
- 2021-04-09
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The invention relates to the technical field of medicine, in particular to a self-microemulsion preparation of axitinib. Background technique
[0002] Axitinib (Axitinib) is a multi-target tyrosine kinase inhibitor developed by Pfizer, which can inhibit vascular endothelial cell growth factor receptors VEGFR1, VEGFR2, VEGFR3, platelet-derived growth factor receptor and c-KIT. It was approved by FDA on January 27, 2012 for advanced kidney cancer that failed other systemic treatments. The currently marketed axitinib products are tablets.
[0003] Axitinib is a white powder with a melting point of 218.4°C. It is slightly soluble in polyethylene glycol 400, slightly soluble in methanol or ethanol, very slightly soluble in acetonitrile, and almost insoluble in water. It is unstable to light, heat, and humidity. prone to degradation. Its solubility in pH 1.2 hydrochloric acid solution at 20°C is 0.8 mg / ml, and in pH 6.8 phosphate buffer solution is 0.2 mi...